CDK

Cat. No.

A54214

CAS No.

326823-27-2

PNU-292137

PNU-292137 is a potent inhibitor of Cyclin-Dependent Kinase 2 (CDK2), with IC50 values of 37 nM for the CDK2/cyclin A complex and 92 nM for the CDK2/cyclin E complex. This compound interacts with the hydrophobic pocket located within the ATP binding site of CDK2, effectively hindering tumor cell proliferation in human colon and prostate cancer cell lines. Additionally, PNU-292137 demonstrates significant antitumor activity in vivo, evidenced by a tumor growth inhibition greater than 50% in mouse xenograft models, making it a valuable tool for cancer research.

Cat. No.

A54215

CAS No.

1868086-40-1

Eciruciclib

Eciruciclib is a potent inhibitor of cyclin-dependent kinases (CDKs), primarily targeting CDK2, CDK4, and CDK6. It demonstrates significant antineoplastic activity, making it a valuable tool for cancer research. This compound is employed in studies aimed at understanding cell cycle regulation and developing targeted therapies for various malignancies.

Cat. No.

A54218

CAS No.

507487-89-0

CK7

CK7 is a potent inhibitor of cyclin-dependent kinases Cdk2 and Cdk9. It demonstrates significant biological activity in modulating cell cycle progression and transcriptional regulation. This reagent is particularly useful in research applications focused on cancer biology and the development of novel therapeutics targeting the cell cycle. Additionally, CK7 serves as a synthetic precursor for the production of Nek1 inhibitors BSc5231 and BSc5367.

Cat. No.

A54219

CAS No.

359886-84-3

CGP-82996

Synonyms: CINK4

CGP-82996 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It demonstrates IC50 values of 1.5 μM, 5.6 μM, and 25 μM against CDK4/cyclin D1, CDK6/cyclin D1, and Cdk5/p35, respectively. This compound effectively induces apoptosis in U2OS cancer cells, making it a valuable tool in cancer research to study the modulation of cell cycle progression and cancer cell viability.

Cat. No.

A54220

CAS No.

779353-02-5

CDK-IN-6

CDK-IN-6 is a pyrazolo[1,5-a]pyrimidine compound that functions as a cyclin-dependent kinase (CDK) inhibitor. This compound exhibits significant anticancer activity by hindering cell cycle progression, particularly in malignant cells. CDK-IN-6 is utilized in research to explore pathways involved in cancer proliferation and may serve as a valuable tool for investigating therapeutic strategies targeting CDK regulation in various tumors.

Cat. No.

A54222

CAS No.

158982-15-1

N9-Isopropylolomoucine

N9-Isopropylolomoucine is a selective inhibitor of cyclin-dependent kinases (CDKs), specifically targeting CCNB1/CDK1. It plays a critical role in regulating cell cycle progression and mitotic processes. This compound is valuable in cancer research for studying cell proliferation and exploring therapeutic strategies that disrupt tumor growth by targeting CDK activity.

Cat. No.

A54224

CAS No.

140651-18-9

CAN508

CAN508 is a potent ATP-competitive inhibitor of the CDK9/cyclin T1 complex, displaying an IC50 of 0.35 μM. This compound demonstrates a remarkable 38-fold selectivity for CDK9/cyclin T over other cyclin-dependent kinases, making it a valuable tool for investigating transcriptional regulation. Its antitumor activity positions CAN508 as a relevant candidate for research into cancer therapeutics and related signaling pathways.

Cat. No.

A54225

CAS No.

2445205-24-1

CDK4/6-IN-12

CDK4/6-IN-12 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It demonstrates significant enzymatic inhibitory activity, with IC50 values of 592.3 nM for CDK4 and 3090 nM for CDK6. This compound is valuable for cancer research, particularly in studies exploring cell cycle regulation and therapeutic strategies targeting CDK4/6 in tumor cells.

Cat. No.

A54226

CAS No.

2651200-35-8

CDK12-IN-5

CDK12-IN-5 is a selective inhibitor of cyclin-dependent kinase 12 (CDK12), exhibiting a potent inhibitory activity with an IC50 of 23.9 nM in the presence of high ATP (2 mM). This compound shows no significant inhibition against CDK2/Cyclin E or CDK9/Cyclin T1, with IC50 values of 173 μM and 127 μM, respectively, under the same conditions. CDK12-IN-5 is valuable for studies investigating the role of CDK12 in transcriptional regulation and its implications in cancer research.

Cat. No.

A54227

CAS No.

2639540-19-3

CDK5-IN-1

CDK5-IN-1 is a selective inhibitor of cyclin-dependent kinase 5 (CDK5), exhibiting an inhibitory concentration (IC50) of less than 10 nM. This compound demonstrates over 100-fold specificity for CDK5 compared to CDK2, making it a valuable tool for studying CDK5-related pathways. CDK5-IN-1 is applicable in research on kidney diseases and offers insights into the molecular mechanisms governing renal function and pathology.

Cat. No.

A54228

CAS No.

101622-53-1

CDK2-IN-13

CDK2-IN-13 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), exhibiting an IC50 value of 12 µM. This compound is primarily utilized in cancer research to study the role of CDK2 in cell cycle regulation and tumor proliferation. Its ability to modulate CDK2 activity makes it a valuable tool for investigating potential therapeutic strategies in oncology.

Cat. No.

A54231

CAS No.

2741262-15-5

FMF-04-159-R

FMF-04-159-R is an inhibitor of cyclin-dependent kinases CDK14 and CDK16, exhibiting IC50 values of 5.9 nM and 139.1 nM, respectively. This compound is primarily utilized in research to explore the roles of CDK14 and CDK16 in cell cycle regulation and transcriptional control. Its selective inhibition may provide insights into therapeutic strategies for diseases linked to dysregulated kinase activity.

Cat. No.

A54232

CAS No.

2688098-02-2

CDK4/6-IN-9

CDK4/6-IN-9 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), exhibiting an IC50 of 905 nM for the CDK6/cyclin D1 complex. This compound demonstrates significant potential in the investigation of multiple myeloma (MM) biology and therapeutic strategies. It is designed to facilitate research focused on cell cycle regulation and the oncogenic pathways associated with MM.

Cat. No.

A54234

CAS No.

2920469-94-7

(2S,3R)-Voruciclib hydrochloride

(2S,3R)-Voruciclib hydrochloride is a selective inhibitor of cyclin-dependent kinases (CDKs), demonstrating potent activity against various CDK isoforms. This compound is primarily used in the study of cell cycle regulation and cancer biology, providing insights into mechanisms of proliferation and tumor growth. Its oral bioavailability makes it a valuable tool for in vivo research applications in cancer therapeutics.

Cat. No.

A54235

CAS No.

1983983-64-7

Tanuxiciclib

Tanuxiciclib is a selective cyclin-dependent kinase (CDK) inhibitor that targets multiple CDK family members. It exhibits potent antitumor activity through the inhibition of cell cycle progression, making it a valuable tool in cancer research. This compound is utilized in studies investigating cell proliferation, apoptosis, and the mechanisms of cancer cell survival, offering potential insights into novel therapeutic strategies.

Cat. No.

A54236

CAS No.

2185859-59-8

(S)-Ebvaciclib

Synonyms: (S)-PF-06873600

(S)-Ebvaciclib is the S enantiomer of PF-06873600, a selective and orally bioavailable inhibitor of cyclin-dependent kinases (CDKs). This compound has shown potential in modulating cell cycle progression and is useful for research applications related to cancer therapeutics. Its specificity toward CDKs makes it a valuable tool for studying cell proliferation and relevant signaling pathways in various disease models.

Cat. No.

A54237

CAS No.

141992-47-4

NSC 625987

NSC 625987 is a potent CDK4 inhibitor, exhibiting an IC50 of 0.2 μM for the CDK4:cyclin D1 complex. This compound demonstrates more than 500-fold selectivity for CDK4 compared to CDK2, making it a valuable tool for studying cell cycle regulation and cancer biology. Its specificity and efficacy make NSC 625987 suitable for research applications aimed at understanding CDK4's role in tumor proliferation and potential therapeutic strategies.

Cat. No.

A54238

CAS No.

3054791-71-5

SHR5428

SHR5428 is a selective and noncovalent inhibitor of cyclin-dependent kinase 7 (CDK7), exhibiting potent enzymatic activity with an IC50 of 2.3 nM. This compound effectively inhibits cellular activity in triple-negative breast cancer models, specifically in MDA-MB-468 cells, with an IC50 of 6.6 nM. SHR5428 is suitable for research applications involving cell cycle regulation and therapeutic development for aggressive breast cancer forms.

Cat. No.

A54240

CAS No.

2762279-02-5

ZDLD20

ZDLD20 is a selective inhibitor of CDK4, exhibiting an IC50 value of 6.51 μM. This β-carboline compound demonstrates significant anti-cancer properties, particularly against HCT116 cells, by inhibiting colony formation, invasion, and migration. Additionally, ZDLD20 promotes apoptosis and induces G1 phase cell cycle arrest, making it a valuable tool for cancer research and therapeutic development.

Cat. No.

A54241

CAS No.

3065079-44-6

CDK2-IN-40

CDK2-IN-40 is a potent inhibitor of Cyclin-dependent kinase 2 (CDK2), demonstrating effective inhibition of the CDK2/Cyclin E1 complex with an IC50 value of ≤ 10 nM. This compound plays a significant role in regulating cell cycle progression and is valuable for research applications related to cancer therapy and cellular proliferation studies. CDK2-IN-40 can be utilized to explore the implications of CDK2 inhibition in various biological contexts.

Cat. No.

A54242

CAS No.

2648334-53-4

DDO-6079

DDO-6079 is a potent inhibitor of CDC37, a key chaperone protein involved in the stabilization and activation of various client proteins. By binding to an allosteric site on CDC37, DDO-6079 disrupts the HSP90-CDC37 and CDC37-CDK4/6 chaperone complexes, leading to reduced thermostability of CDK6. This compound is valuable for research applications aimed at understanding the role of CDC37 in cellular signaling and cancer biology.

Cat. No.

A54243

CAS No.

1453833-30-1

LDC3140

LDC3140 is a potent and selective inhibitor of cyclin-dependent kinase 7 (CDK7) with an IC50 of less than 5 nM. By targeting CDK7, LDC3140 disrupts cell cycle regulation, resulting in cell cycle arrest and reduced proliferation of tumor cells. This compound serves as a valuable tool for research focused on cancer therapeutics and the mechanistic understanding of cell cycle dynamics in cancer biology.

Cat. No.

A54244

CAS No.

3542-63-0

CDK9-IN-10

CDK9-IN-10 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), effectively targeting the transcriptional regulation pathways. This compound serves as a crucial ligand for the PROTAC CDK9 degrader-2, facilitating targeted degradation of CDK9 in cellular studies. Its applications include investigations into oncogenic processes and transcriptional dysregulation, making it a valuable tool for cancer research and drug discovery.

Cat. No.

A54245

CAS No.

2650640-17-6

CDK9-IN-14

CDK9-IN-14 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), exhibiting an IC50 value of 6.92 nM. This compound demonstrates significant inhibitory activity against MV4;11 cells and exhibits efficacy in in vivo tumor models. Additionally, CDK9-IN-14 shows favorable selectivity and a low toxicity profile, making it suitable for various cancer research applications aimed at targeting transcriptional regulation pathways.

Cat. No.

A54247

CAS No.

2250279-81-1

Atuveciclib S-Enantiomer

Synonyms: BAY-1143572 S-Enantiomer

Atuveciclib S-Enantiomer is a potent and selective inhibitor of cyclin-dependent kinase 9 (CDK9). With an IC50 of 16 nM, it effectively inhibits the CDK9/CycT1 complex, playing a crucial role in regulating transcription and cell cycle progression. This compound is primarily utilized in research applications targeting cancer therapeutics and studying transcriptional regulation mechanisms.